RARA and acute myeloid leukemia: Based on these findings, the ELN Working Party consensus document on MRD in AML (6), indicates that molecular assessment for NPM1 mutations, RUNX1-RUNX1T1, CBFB-MYH11, and PML-RARA fusion transcripts, should be performed at diagnosis, at least after two cycles of induction/consolidation therapy, and every 3 months, for 24 months after the end of treatment.